| Literature DB >> 33232448 |
Christophe d'Enfert1, Ann-Kristin Kaune2, Leovigildo-Rey Alaban3,4, Sayoni Chakraborty5,6, Nathaniel Cole7, Margot Delavy1,4, Daria Kosmala1,4, Benoît Marsaux8,9, Ricardo Fróis-Martins10,11, Moran Morelli12, Diletta Rosati13, Marisa Valentine5, Zixuan Xie14, Yoan Emritloll1, Peter A Warn15, Frédéric Bequet3, Marie-Elisabeth Bougnoux1, Stephanie Bornes16, Mark S Gresnigt5, Bernhard Hube5, Ilse D Jacobsen5, Mélanie Legrand1, Salomé Leibundgut-Landmann10,11, Chaysavanh Manichanh14, Carol A Munro2, Mihai G Netea13, Karla Queiroz12, Karine Roget17, Vincent Thomas3, Claudia Thoral17, Pieter Van den Abbeele8, Alan W Walker7, Alistair J P Brown18.
Abstract
Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients.Entities:
Keywords: zzm321990 Candidazzm321990 ; zzm321990 Candida infections; antifungal immunity; fungal variability; fungus-host-microbiota interactions; microbiota; microbiota variability; mycobiota; patient variability
Mesh:
Year: 2021 PMID: 33232448 PMCID: PMC8100220 DOI: 10.1093/femsre/fuaa060
Source DB: PubMed Journal: FEMS Microbiol Rev ISSN: 0168-6445 Impact factor: 16.408